AR067537A1 - Purificacion de polipeptidos pegilados - Google Patents

Purificacion de polipeptidos pegilados

Info

Publication number
AR067537A1
AR067537A1 ARP080103023A ARP080103023A AR067537A1 AR 067537 A1 AR067537 A1 AR 067537A1 AR P080103023 A ARP080103023 A AR P080103023A AR P080103023 A ARP080103023 A AR P080103023A AR 067537 A1 AR067537 A1 AR 067537A1
Authority
AR
Argentina
Prior art keywords
mono
cation exchange
erythropoietin
pegylated
purification
Prior art date
Application number
ARP080103023A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40120288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067537(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR067537A1 publication Critical patent/AR067537A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para producir una eritropoyetina mono-pegilada en una forma sustancialmente homogénea. Reivindicacion 1: Método para la purificacion de una eritropoyetina mono-PEGilada que consiste en los pasos de proporcionar una solucion que contiene eritropoyetina mono-, poli- y no-PEGilada, de realizar dos pasos consecutivos de cromatografía de intercambio cationico y de recuperar la eritropoyetina mono-PEGilada purificada en el segundo paso de la cromatografía de intercambio cationico, caracterizado porque en los dos pasos de cromatografía de intercambio cationico se emplea el mismo tipo de material de intercambio cationico.
ARP080103023A 2007-07-17 2008-07-14 Purificacion de polipeptidos pegilados AR067537A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07013959 2007-07-17

Publications (1)

Publication Number Publication Date
AR067537A1 true AR067537A1 (es) 2009-10-14

Family

ID=40120288

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080103023A AR067537A1 (es) 2007-07-17 2008-07-14 Purificacion de polipeptidos pegilados
ARP180101676 AR112300A2 (es) 2007-07-17 2018-06-14 Purificación de polipéptidos pegilados

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180101676 AR112300A2 (es) 2007-07-17 2018-06-14 Purificación de polipéptidos pegilados

Country Status (21)

Country Link
US (2) US8138317B2 (es)
EP (1) EP2178900B1 (es)
JP (2) JP5307808B2 (es)
KR (1) KR101163297B1 (es)
CN (1) CN101889023B (es)
AR (2) AR067537A1 (es)
AT (1) ATE556086T1 (es)
AU (1) AU2008277887B2 (es)
BR (1) BRPI0813830A2 (es)
CA (1) CA2692612C (es)
CL (1) CL2008002053A1 (es)
DK (1) DK2178900T3 (es)
ES (1) ES2386323T3 (es)
IL (1) IL202940A (es)
PE (1) PE20090823A1 (es)
PL (1) PL2178900T3 (es)
PT (1) PT2178900E (es)
RU (1) RU2476439C2 (es)
TW (1) TWI363060B (es)
WO (1) WO2009010270A2 (es)
ZA (1) ZA201000283B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
CA2736141C (en) * 2008-09-23 2018-03-20 F. Hoffmann-La Roche Ag Purification of erythropoietin
WO2011035282A1 (en) * 2009-09-21 2011-03-24 Ge Healthcare Bio-Sciences Ab Dual capture separation
WO2012035037A1 (en) * 2010-09-14 2012-03-22 F. Hoffmann-La Roche Ag Method for purifying pegylated erythropoietin
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
CN105820232B (zh) * 2016-04-08 2019-05-17 昂德生物药业有限公司 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
EP3484911B1 (en) 2016-07-15 2020-11-04 H. Hoffnabb-La Roche Ag Method for purifying pegylated erythropoietin
CN111801120A (zh) * 2017-12-29 2020-10-20 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
PL3731873T3 (pl) * 2017-12-29 2022-04-25 F. Hoffmann-La Roche Ag Sposób dostarczania kompozycji pegylowanego białka
SG11202005990RA (en) * 2017-12-29 2020-07-29 Hoffmann La Roche Process for providing pegylated protein composition
WO2020096958A1 (en) * 2018-11-05 2020-05-14 Bristol-Myers Squibb Company Method for purifying pegylated protein
US20240092883A1 (en) * 2019-10-11 2024-03-21 Coherus Biosciences, Inc. Methods of purifying ranibizumab or a ranibizumab variant

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE69032809T2 (de) 1989-11-06 1999-07-08 Cell Genesys, Inc., Foster City, Calif. Herstellung von Proteinen mittels homologer Rekombination
DE69034135T3 (de) 1989-12-22 2012-08-23 Laboratoires Serono S.A. DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
FR2656531B1 (fr) 1989-12-29 1992-04-24 Sanofi Sa Promoteur artificiel pour l'expression de proteines dans le levure.
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
JP2826362B2 (ja) 1990-02-13 1998-11-18 三井化学株式会社 オレフィン重合用固体触媒の製造方法、オレフィン重合用固体触媒およびオレフィンの重合方法
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
CH686212A5 (de) 1992-03-07 1996-02-15 Buehler Ag Geb Verfahren und Vorrichtung zur Manipulation und Portionieren von langen Teigwaren.
DE4118912C1 (es) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
EP0536447A1 (en) 1991-10-11 1993-04-14 Koninklijke Emballage Industrie Van Leer B.V. Exposure meter for use with induction heat sealing of containers
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0651761B1 (en) * 1992-07-13 2002-10-09 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5264555A (en) 1992-07-14 1993-11-23 Enzon, Inc. Process for hemoglobin extraction and purification
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5437989A (en) * 1992-12-30 1995-08-01 Hoffmann-La Roche Inc. Alcohol/aldehyde dehydrogenase from Gluconobacter oxydans DSM 4025 FERM BP-3812
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
DE19535571A1 (de) * 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
AU7907398A (en) 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
DE19734293A1 (de) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
EP1147134B1 (en) 1999-01-26 2006-10-11 Neurosearch A/S Novel potassium channels and genes encoding these potassium channels
CZ300546B6 (cs) 1999-01-29 2009-06-10 Amgen, Inc. Fyziologicky aktivní konjugát, prostredek a zpusob prípravy
US6583273B1 (en) 1999-05-10 2003-06-24 Ciba Specialty Chemicals Corporation Azo dyes, process for their preparation and their use for dyeing or printing natural or synthetic materials
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
WO2001058957A2 (en) * 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
BRPI0110914B8 (pt) * 2000-05-15 2021-05-25 Hoffmann La Roche 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
ES2361824T3 (es) * 2000-12-20 2011-06-22 F. Hoffmann-La Roche Ag Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US6797299B2 (en) 2002-02-05 2004-09-28 Great Wall Enterprise Co., Ltd. Desalting method for nutritional supplements with animal protein
SE526227C2 (sv) 2002-05-15 2005-08-02 North China Pharmaceutical Group Metod för rening av rekombinant humant serumalbumin
WO2004009627A1 (en) * 2002-07-19 2004-01-29 Cangene Corporation Pegylated erythropoietic compounds
EP1526872A1 (en) * 2002-07-24 2005-05-04 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
AU2003265994B2 (en) 2002-09-11 2010-04-01 Genentech, Inc. Protein purification
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
SE0401951D0 (sv) 2004-07-29 2004-07-29 Amersham Biosciences Ab Chromatography method
MX2007007580A (es) * 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
JP5148484B2 (ja) * 2005-05-24 2013-02-20 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ クロマトグラフィーマトリックスの再生
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
GB2428018B (en) 2005-07-06 2010-07-28 Acco Uk Ltd Stapling device
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
SI1931704T1 (sl) 2005-10-04 2011-04-29 Zymogenetics L L C Priprava in čiščenje IL-29
WO2008010061A2 (en) 2006-07-17 2008-01-24 Glenmark Pharmaceuticals S.A. 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.

Also Published As

Publication number Publication date
CN101889023B (zh) 2013-03-20
RU2010105303A (ru) 2011-08-27
EP2178900A2 (en) 2010-04-28
WO2009010270A3 (en) 2009-04-30
PL2178900T3 (pl) 2012-10-31
EP2178900B1 (en) 2012-05-02
US20110118448A1 (en) 2011-05-19
DK2178900T3 (da) 2012-06-25
CA2692612A1 (en) 2009-01-22
US8889837B2 (en) 2014-11-18
JP2013189457A (ja) 2013-09-26
CA2692612C (en) 2015-02-10
WO2009010270A2 (en) 2009-01-22
CN101889023A (zh) 2010-11-17
TWI363060B (en) 2012-05-01
KR101163297B1 (ko) 2012-07-05
TW200914463A (en) 2009-04-01
KR20100072169A (ko) 2010-06-30
CL2008002053A1 (es) 2009-05-22
JP2010533664A (ja) 2010-10-28
AR112300A2 (es) 2019-10-16
US8138317B2 (en) 2012-03-20
ZA201000283B (en) 2011-06-29
RU2476439C2 (ru) 2013-02-27
WO2009010270A8 (en) 2010-04-29
US20090118476A1 (en) 2009-05-07
PE20090823A1 (es) 2009-06-27
PT2178900E (pt) 2012-06-01
JP5814978B2 (ja) 2015-11-17
AU2008277887A1 (en) 2009-01-22
AU2008277887B2 (en) 2012-12-13
IL202940A (en) 2015-07-30
BRPI0813830A2 (pt) 2015-01-06
ES2386323T3 (es) 2012-08-17
ATE556086T1 (de) 2012-05-15
JP5307808B2 (ja) 2013-10-02

Similar Documents

Publication Publication Date Title
AR067537A1 (es) Purificacion de polipeptidos pegilados
AR110693A2 (es) Métodos cromatográficos
ECSP099688A (es) Moléculas y métodos para modular la pro-proteína
BRPI0816449A2 (pt) Material compósito, e, processo para produzir o mesmo
FR2916755B1 (fr) Procede de preparation d'(hydro)(chloro)(fluoro)olefines
CL2011000613A1 (es) Polipeptido de eritropoyetina felina (fepo) que comprende un aminoacido no codificado de manera natural; metodo para preparar dicho polipeptido; composicion que comprende dicho polipeptido.
BRPI0821708A2 (pt) Processo para obter fluorometil 1,1,1,3,3,3-hexa-fluorisopropil éter purificado
CR8537A (es) Moduladores de HM74 de Oxidecahidronaftaleno
BRPI0511984A (pt) produto para amaciamento à base de água e processo para preparo e uso do mesmo
ITTO20040702A1 (it) Procedimento per la produzione di lastre di materiale plastico trasparente con parti sovrainiettate non trasparenti
BRPI0609064A2 (pt) processo para produzir uma composição enriquecida.
CL2007002565A1 (es) Proceso para preparar 2-cloro-5-(3-oxopropil)-n-(triciclo(3.3.1.1)dec-1-ilmetil)-benzamida.
ITPG20050033A1 (it) Raggi uguali con le due spinte del tirante ai lati delle due ruote.
TH81136S (th) หลอดไฟฟ้า
BR112016016706A2 (pt) Processo para a purificação de a-olefinas lineares, processo para a purificação de aminas e dióxido de carbono a partir de complexos de amina-dióxido de carbono, processo para a preparação de a-olefinas lineares, e aparelho
BRPI0501809A (pt) pneus trapézio sport
ITBG20070019A1 (it) Copertura di protezione lampadina particolarmente per lampade per bambini.
ES1056221Y (es) Etiqueta clip como suplemento de ampliacion de caracteristicas en los portaprecios de productos.
TH77722EX (th) รองเท้า
TH110765S (th) เครื่องมือตรวจสอบเพชร
AR025773A4 (es) Disposicion para separar el palito, fibra, pelusas del te
TH81138S (th) หลอดไฟฟ้า
TH81137S (th) หลอดไฟฟ้า
RU2006119731A (ru) Рельс
TH38973S1 (th) ฐานอ่างล้างหน้า

Legal Events

Date Code Title Description
FG Grant, registration